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Synthesis of highly functionalized oligobenzamide
proteomimetic foldamers by late stage introduction
of sensitive groups†
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Adam Nelsona,b and Andrew J. Wilson*a,b
α-Helix proteomimetics represent an emerging class of ligands that can be used to inhibit an array of helix
mediated protein–protein interactions. Within this class of inhibitor, aromatic oligobenzamide foldamers
have been widely and successfully used. This manuscript describes alternative syntheses of these com-
pounds that can be used to access mimetics that are challenging to synthesize using previously described
methodologies, permitting access to compounds functionalized with multiple sensitive side chains and
accelerated library assembly through late stage derivatisation.
Introduction
An on-going challenge in chemical biology is the inhibition of
protein–protein interactions (PPIs) using designed small mole-
cules.1,2 An approach to the targeting of PPIs that has gained
attention is the use of secondary structure mimics3,4 which
have been referred to as α-helix mimetics, proteomimetics,5
topographical mimics and pharmacological chaperones.6 Oligo-
benzamide helix mimetics (e.g. A–D Fig. 1) have been shown
by us and others to act as eﬀective and selective inhibitors of a
range of PPIs.7–20 Our group has developed two general
approaches for synthesis21 of these compounds (Scheme 1a
and b): (i) iterative solution phase coupling of nitro-masked
monomers with carboxy-protected terminal anilines, followed
by unmasking of the latent amine10,12,13,22–24 and (ii) N-term-
inal extension with Fmoc protected monomers followed by de-
protection in solution or on solid-supported resin.7–9,11,25–28
Herein, we report alternative complementary routes towards
highly functionalised compounds. These comprise (a) coup-
ling of unfunctionalized monomers followed by subsequent
introduction of the amino acid side chain mimicking group
(Scheme 1c) and (b) the preparation of compounds bearing
side chain functionality through late stage functionalization
on the fully assembled scaﬀold (Scheme 1d).
HIF-1 is an emerging, but not yet fully validated target for
cancer chemotherapy; the interaction of HIF-1α with CREB
binding protein (CBP)/p300 plays a major role in regulating
the hypoxic response and as such its inhibition represents an
attractive approach to prevent development of new vasculature
by hypoxic tumours. The HIF-1α/p300 interaction is substan-
tially mediated by the binding of HIF-1α around the p300 CH1
domain and involves 3 regions which adopt a helical confor-
mation on binding to p300 (Fig 2a).29,30 We recently reported
that helix 3 plays the dominant role in mediating potency of
recognition but that helix 2, either as a fusion with helix 1 or 3
plays a role in binding (Fig. 2b).31 We also demonstrated that
helix 3 could be eﬀectively mimicked using a 3-O-alkylated aro-
Fig. 1 Structures of aromatic oligoamide helix mimetics A–D.
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matic oligoamide helix mimetic (Fig 2c). Motivated by this, we
sought to synthesise mimics of the helix-2 sequence and
explore the structure activity relationship around the helix-
3 mimetic. Thus, using the HIF-1α/p300 interaction as a
model, the two new synthetic methods described below allow
further analyses of α-helix mimicry of the p300 binding HIF-1α
transactivation sequence, but equally may be applied to
further studies on any of the 2 or 3-O-alkylated helix mimetics
described to date.
Results and discussion
Highly functionalised compounds – helix 2
Initially, we sought to prepare mimetics capable of recapitulat-
ing the side chains of a diﬀerent region of the HIF-1α peptide
to corroborate our observations from peptide binding studies.
The helix 2 region of the HIF-1α CTAD contains two reported
“hot-spot” residues which are also the sites of post-transla-
tional modifications, Cys800 and Asn804 as shown in Fig. 2.
33,34
Initial attempts to prepare helix 2 mimics (Fig. 2c) using
monomers designed to mimic Asn, Cys and Ser (see ESI,
Scheme S2† for structures and synthesis) and either of our
established protocols were hampered by ineﬃcient coupling
between the respective amine and acid building blocks. We
tentatively suggest that the lack of coupling arises as a conse-
quence of the extra steric bulk conferred by the large protect-
ing groups on each monomer (see Table S1†) along with the
poor nucleophilicity of ortho-amino phenols.25,35 After screen-
ing a range of amide bond forming conditions (see ESI,
Table S1†), an alternative synthetic strategy was investigated
building on the work of Ahn;35 this ligation approach exploits
the eﬃciency of intramolecular acylation. The nitro acid
monomer 1 was reacted with methyl 4-amino-3-hydroxybenzo-
ate 2 to give a 1 : 9 mixture of the amide 3 and the ester 4;
O- to N-acyl transfer was then promoted by treating the mixture
Scheme 1 General strategies for aromatic oligoamide helix mimetics synthesis (a) N-terminal elongation with nitro-functionalised monomers (b)
solid-phase synthesis using Fmoc strategy (c) O–N-acyl-shift for post monomer coupling functional group introduction (d) late stage
functionalization.
Fig. 2 (a) Structure of the HIF-1α CTAD/p300 CH1 domain complex
(PDB ID: 1L8C,32 p300 green, HIF-1α, blue) together with 3-O-alkylated
aromatic oligoamide helix mimetics for helix 2 and 3 of HIF-1α designed
on the basis of (b) binding studies reported previously (regions
conﬁrmed to contribute aﬃnity shown in purple and other regions
shown in blue) (c) Modelling of helix 2 mimetic (hot spot residues on
helix (in blue) are highlighted).
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with caesium carbonate to aﬀord the desired compound 3 in a
moderate 44% yield. The second side chain was then intro-
duced with 2-bromo-N-(triphenylmethyl)-acetamide before
final reduction, hydrolysis and deprotection to yield the
desired, densely functionalised dimer 5 as shown in Scheme 2.
In the design of 5 an alcohol side chain was used on the
N-terminal amino benzoic acid monomer in lieu of a thiol.36,37
The O- to N-acyl synthetic method was also employed to syn-
thesise the reverse side chain orientation of 5 (see ESI†). In
principle this synthetic method should be fully compatible
with the solid-phase synthesis methodologies previously
reported and facilitate the preparation of highly functionalised
helix mimetics for use against other targets.
Late stage derivatisation – helix 3
Having demonstrated synthetic feasibility for late stage alkyl-
ation of the phenolic position in the course of synthesising
dimer 5 (see above), we further adapted this approach to
permit late stage derivatisation of the trimeric oligobenzamide
scaﬀold (Fig. 1a) and rapid library generation for structure
activity relationship (SAR) studies around our initial helix 3
inhibitors.38 Late stage derivatisation reduces the requirement
to build and assemble large sets of monomers and should
allow the incorporation of delicate functionalities (e.g.
trifluoromethyl diazirines to support proteomics analyses and
binding site identification by cross-linking).
Using the recently identified proteomimetic inhibitor (see
Fig. 2a) of the HIF-1α/p300 interaction as inspiration,10 a
series of compounds with cleavable protecting groups was pre-
pared, e.g. 6b. Phenolic allyl ethers are readily cleaved via the
formation of a π-allyl complex with palladium(0) but are rela-
tively inert to other conditions. This makes then ideal for use
in the late stage derivatisation of oligobenzamides. Indeed, the
allyl groups in 6a–c were readily cleaved with palladium(0)
tetrakis(triphenylphosphine) employing toluene sulfinic acid as
a scavenger (Scheme 3 for a representative example (6b→ 7b)).
The phenols 7a–c could then be functionalised by employ-
ing Mitsunobu chemistry or alkylation with an appropriate
halide yielding functionalized helix mimetics which, upon
reduction of the aryl nitro group and ester hydrolysis in one
pot, aﬀord final compounds 8a–i (Table 1), following purifi-
cation (Scheme 3 for a representative example (7b → 8e)). This
approach was thus employed to prepare a small library of com-
pounds 8a–i with previously unreported side chain combi-
nations. Alcohols and alkyl halides were selected to challenge
the synthetic approach (focusing on tertiary amines) rather
than a specific intention to develop optimised inhibitors.
As a further illustrative example of the power of the
approach, we incorporated a trifluoromethyl diazirine func-
tionality into the oligobenzamide for photo-crosslinking
experiments. The fragile diazirine would not be stable to the
reductive conditions required to reduce the nitro groups.
Scheme 2 Synthesis of helix 2 mimetic by O–N-acyl shift and alkyl-
ation sequence.
Scheme 3 Late stage helix mimetic derivatisation (a) representative
synthetic route for 6b (b) structures of compounds 6a and 6b.
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However, using the late stage methodology described above,
the aryl trifluoromethyl diazirine was incorporated follow-
ing a slightly modified sequence following all the required
reductions. By selectively, and irreversibly, deprotonating the
phenol 7b with sodium hydride then treating with the iodide
9, the desired functionality could be introduced regioselec-
tively. Final ester hydrolysis was performed in situ by treating
the reaction mixture with sodium hydroxide to yield the photo-
crosslinking helix mimetic 8j. 8k was synthesized using a
similar sequence of steps from compound 6c (see ESI† for
details) (Table 1).
Biophysical analyses
Using a previously described fluorescence anisotropy competi-
tive HIF-1α/p300 assay,10,31 the helix 2 mimetic 5 was shown to
be ineﬀective as a HIF-1α/p300 inhibitor; this is surprising
given that the group of Arora had previously shown a hydro-
gen-bond surrogate constrained peptide derived from helix 2
of HIF-1α was a good HIF-1α/p300 inhibitor39 but is consistent
with our observations that the helix 2 peptide alone is not a
useful inhibitor.31 The compounds prepared by late stage deri-
vatisation (7 and 8) were also screened for activity (Table 1);
they showed reduced activity compared to the previously
reported inhibitors by us and others.10,40 This is consistent
with the hydrophobicity of the binding groove. The diazarine
bearing compound 8k also exhibits reduced binding whereas
8j, was not active in our assay.
In pursuit of preliminary cross-linking studies, compound 8k
was incubated with p300 and irradiated with 365 nM
light followed by LC-MS analysis. LC-MS analysis revealed
almost complete conversion of the diazarine moiety to
carbene quenching products but unfortunately no protein
labelling was observed (see Fig. S3†). The quenched carbene pro-
ducts and absence of cross-linking to protein suggest that the
trifluoromethyl diazarine is exposed to solvent when compound
8k is bound to p300 rather than buried in the protein surface.
Further experiments with other proteins are ongoing.
Conclusions
In summary, we have described methodology that provides
access to challenging aromatic oligoamide sequences and
complements current approaches for the synthesis of these
widely used helix mimetics. This approach may be useful in
building up a picture of structure activity relationships (SAR)
and is complementary to solution and SPS strategies for helix
mimetic assembly useful for library production and initial
screening.8,18,25 To appreciate the power of this alternative syn-
thetic approach, compounds 8b,d–e,g–i were prepared in a
total of 39 synthetic steps whereas by contrast, it would have
required 51 synthetic steps to prepare this library using our
previously described methods.10,14,25 We have exemplified this
with our preliminary results for inhibition of a key target in
tumour metabolism, HIF-1α/p300.
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